Patients with schizophrenia exhibit disturbances in information processing and cognitive impairment. These disturbances can be recapitulated in rodents and are clinically investigated with different paradigms of auditory event related potentials (ERP) as well as by appropriate cognitive tests aligned to specific cognitive domains, recommended by MATRICS, CNTRICS and TURNS initiatives.
We routinely use two approaches to support decision-making with novel test compounds: i) Pharmacological (Phencyclidine (PCP), Methylazoxymethanol acetate (MAM), Ketamine); and ii) Environmental: Social Isolation (Lister Hooded rats).
Our experimental protocols applied to our models of Schizophrenia allows the electrophysiological detection of translational ERP endpoints such as N1 and MMN-like responses in standard and oddball paradigm stimuli in response to test compound(s). Furthermore our battery of rodent cognition tests (e.g. Novel Object Recognition (NOR), Attentional Set-Shifting (ASS) and touchscreen-based paradigms) provides the opportunity for assessing whether novel test compounds have the potential utility for treating a range of cognitive impairments associated with schizophrenia.
In addition to the above mentioned assays to model negative symptoms of Schizophrenia, we also offer ‘classical models’ of positive symptoms (e.g amphetamine-evoked behaviour).